Dipeptidyl Peptidase

DPP

Dipeptidyl Peptidases are widely distributed exopeptidases that possess central role in proteolysis. The dipeptidyl peptidase family, including DPP-IV DPP7, DPP8, DPP9, fibroblast activation protein and others, cleave the peptide bond after the penultimate proline residue and are drug target rich.

DPP-IV (DPP4 or CD26) is a serine protease detected on several immune cells and on epithelial cells of various organs. Besides the membrane-bound enzyme, a catalytically active soluble form is detected in several body fluids. Both variants cleave off dipeptides from the N-termini of various chemokines, neuropeptides, and hormones. DPP IV plays a key role in immune-regulation, inflammation, oxidative stress, cell adhesion, and apoptosis by targeting different substrates. DPP IV inhibitors are commonly used as hypoglycemic agents.

DPP8 and DPP9 show DPPIV-like activity and share a very high-sequence similarity to each other. DPP8 and DPP9 are intracellular N-terminal dipeptidyl peptidases (preferentially postproline) associated with pathophysiological roles in immune response and cancer biology.

Dipeptidyl Peptidase Inhibitors

(Rac)-Sitagliptin-d4 hydrochloride

Cat. No.: HY-13749S

(Rac)-Sitagliptin-d4 hydrochloride is a labelled racemic Sitagliptin. Sitagliptin hydrochloride is a potent inhibitor of **DPP4** with an **IC_{50}** of 19 nM in Caco-2 cell extracts.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

(S)-Sitagliptin phosphate

((S)-MK-0431 phosphate)

Cat. No.: HY-13749C

(S)-Sitagliptin phosphate is the less active S-enantiomer of Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC_{50} of 19 nM in Caco-2 cell extracts.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

16-Hydroxycleroda-3,13-dien-15,16-olide

(16ξ-Hydroxycleroda-3,13-dien-15,16-olide)

Cat. No.: HY-N9725

16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent **serine protease dipeptidyl peptidase 4 (DPP-4)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1G244

Cat. No.: HY-116304

1G244 is a potent **DPP8/9** inhibitor with **IC_{50}**s of 12 nM and 84 nM, respectively. 1G244 does not inhibit DPPIV and DPPII. 1G244 induces **apoptosis** in multiple myeloma cells and has anti-myeloma effects.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one

Cat. No.: HY-N8134

2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one is a natural product found in the leaves and stem bark of M. glabra.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Alogliptin

(SYR-322 free base)

Cat. No.: HY-A0023A

Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of **DPP-4** with an **IC_{50}** of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes.



Purity: 99.92%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Alogliptin (13CD3)

(SYR-322 (13CD3))

Cat. No.: HY-A0023AS

Alogliptin 13CD3 (SYR-322 13CD3) is the deuterium labeled Alogliptin. Alogliptin is a potent and selective inhibitor of DPP-4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alogliptin Benzoate

(SYR 322)

Cat. No.: HY-A0023

Alogliptin Benzoate (SYR-322) is a potent, selective and orally active inhibitor of **DPP-4** with an **IC_{50}** of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin Benzoate can be used for the research of type 2 diabetes.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Alogliptin-d3

(SYR-322-d3 free base)

Cat. No.: HY-A0023AS1

Alogliptin-d3 (SYR-322-d3 (free base)) is the deuterium labeled Alogliptin. Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of **DPP-4** with an **IC_{50}** of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 5 mg, 25 mg

Anagliptin

(SK-0403)

Cat. No.: HY-14877

Anagliptin is a highly selective, potent inhibitor of **dipeptidyl peptidase 4 (DPP-4)**, with an **IC_{50}** of 3.8 nM, and less selective at DPP-8/9 (**IC_{50}**, 68, 60 nM, respectively).



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Anagliptin-d6

(SK-0403-d6)

Cat. No.: HY-14877S

Anagliptin-d6 is the deuterium labeled Anagliptin. Anagliptin is a highly selective, potent inhibitor of **dipeptidyl peptidase 4 (DPP-4)**, with an IC_{50} of 3.8 nM, and less selective at DPP-8/9 (IC_{50}, 68, 60 nM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azaleatin

Cat. No.: HY-N7653

Azaleatin is an O-methylated flavonol isolated from Rhododendron species. Azaleatin is a **dipeptidyl peptidase-IV** inhibitor. Azaleatin can be used for the research of type-2 diabetes and obesity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Azaleatin-d3

Cat. No.: HY-N7653S

Azaleatin-d3 is the deuterium labeled Azaleatin. Azaleatin is an O-methylated flavonol isolated from Rhododendron species. Azaleatin is a **dipeptidyl peptidase-IV** inhibitor. Azaleatin can be used for the research of type-2 diabetes and obesity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brensocatib

(AZD7986; INS 1007)

Cat. No.: HY-101056

Brensocatib (AZD7986) is an oral **dipeptidyl peptidase 1** (**DPP1**) inhibitor with **pIC$_{50}$**s of 6.85, 7.6, 7.7, 7.8, and 7.8 in human, mouse, rat, dog and rabbit, respectively.



Purity: 99.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DBPR108

Cat. No.: HY-12528

DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9.



Purity: 98.75%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Diprotin A

(Ile-Pro-Ile)

Cat. No.: HY-111174

Diprotin A (Ile-Pro-Ile) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diprotin A TFA

(Ile-Pro-Ile TFA)

Cat. No.: HY-111174A

Diprotin A TFA (Ile-Pro-Ile TFA) is an inhibitor of dipeptidyl peptidase IV **(DPP-IV)**.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

DPP-IV-IN-1

Cat. No.: HY-U00346

DPP-IV-IN-1 is a potent inhibitor of **dipeptidyl peptidase IV (DPP-IV)**, a highly specific **serine protease**, with an IC_{50} of 4.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

DPP-IV-IN-2

Cat. No.: HY-108319

DPP-IV-IN-2 is an inhibitor of both **dipeptidyl peptidase IV** (**DPIV**) and **DP8/9** with **IC$_{50}$**s of 0.1 and 0.95 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Dutogliptin

(PHX-1149 free base)

Cat. No.: HY-10286

Dutogliptin (PHX-1149 free base) is an orally available, potent, and selective **dipeptidyl peptidase-4** (**DPP4**) inhibitor for the treatment of type 2 diabetes mellitus.



Purity: 99.16%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg

Dutogliptin tartrate

(PHX-1149) Cat. No.: HY-10286A

Dutogliptin tartrate (PHX-1149) is an orally available, potent, and selective **dipeptidyl peptidase-4** (**DPP4**) inhibitor for the treatment of type 2 diabetes mellitus.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Ellipyrone A

Cat. No.: HY-N10360

Ellipyrone A, a γ-pyrone enclosed macrocyclic poyketide, shows inhibition potential against **dipeptidyl peptidase-4 (IC_{50}=0.35mM). Ellipyrone A also has anti-carbolytic property against α-glucosidase (IC_{50}=0.74mM) and α-amylase (IC_{50}=0.59mM)**..



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ellipyrone B

Cat. No.: HY-N10362

Ellipyrone B, an antihyperglycemic γ-pyrone enclosed macrocyclic polyketide, shows inhibition potential against **dipeptidyl peptidase-4 (IC_{50}=0.48mM)**..



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Evogliptin tartrate

(DA-1229 tartrate) Cat. No.: HY-117985B

Evogliptin tartrate is a potent, orally bioavailable and selective **dipeptidyl peptidase-4 (DPP-4)** inhibitor, with antidiabetic activity. Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation.



Purity: 99.96%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gemigliptin

(LC15-0444) Cat. No.: HY-14892

Gemigliptin (LC15-0444) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (**DPP-4**) inhibitor, with an IC_{50} of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Gemigliptin tartrate

(LC15-0444 tartrate) Cat. No.: HY-14892A

Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (**DPP-4**) inhibitor, with an IC_{50} of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Gosogliptin

(PF-00734200; PF-734200) Cat. No.: HY-10287

Gosogliptin is a potent and selective inhibitor of **dipeptidyl peptidase-IV** (**DPP-IV**).



Purity: 99.27%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 20 mg

K579

Cat. No.: HY-103433

K579 is a potent and orally active **dipeptidyl peptidase IV** inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linagliptin

(BI 1356) Cat. No.: HY-10284

Linagliptin is a highly potent, selective **DPP-4** inhibitor with IC_{50} of 1 nM.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Linagliptin-13C,d3

(BI 1356-13C,d3) Cat. No.: HY-10284S1

Linagliptin-13C,d3 is the 13C- and deuterium labeled. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linagliptin-d4

(BI 1356-d4) Cat. No.: HY-10284S

Linagliptin-d4 is deuterium labeled Linagliptin. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nateglinide

(A4166; Senaglinide) Cat. No.: HY-B0422

Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a **DPP IV** inhibitor. Nateglinide inhibits ATP-sensitive K^+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Nateglinide D5

(A4166 D5; Senaglinide D5) Cat. No.: HY-B0422S

Nateglinide D5 is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a **DPP IV** inhibitor. Nateglinide inhibits ATP-sensitive K^+ channels in pancreatic β-cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NDMC101

Cat. No.: HY-124958

NDMC101 is a potent **osteoclastogenesis** inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via **DPP4** inhibition.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NVP-DPP728

Cat. No.: HY-14292

NVP-DPP728 is a potent, reversible and nitrile-dependent **dipeptidyl peptidase IV (DPP-IV)** inhibitor. NVP-DPP728 can inhibit human DPP-IV amidolytic activity with a K_i of 11 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-DPP728 dihydrochloride

Cat. No.: HY-14293

NVP-DPP728 dihydrochloride is a potent, selective and orally active dipeptidyl peptidase IV (**DPP-IV**) inhibitor with a K_i of 11 nM. NVP-DPP728 dihydrochloride can be used for the research of diabetes mellitus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Omarigliptin

(MK-3102) Cat. No.: HY-15981

Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor with IC50 of 1.6 nM; highly selective over all proteases tested (IC50 > 67 μM).



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

P32/98

Cat. No.: HY-129736A

P32/98 is a potent inhibitor of **dipeptidyl peptidase IV**. P32/98 improves glucose tolerance, insulin sensitivity and β-cell responsiveness in preclinical studies using the fatty Zucker rat, an animal model for IGT (impaired glucose tolerance).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prodipine hydrochloride

Cat. No.: HY-101605

Prodipine, a diphenyl-phosphonate derivative. The IC_{50}s of Prodipine for purified and plasma **Dipeptidyl peptidase IV** (**DPP IV**) from the rabbit are 4.5 μM and 30 μM, respectively.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 1 mg

Prolyl Endopeptidase Inhibitor 1

(Boc-Pro-prolinal; (Boc)-Prolyl-prolinal; BPP) Cat. No.: HY-113951

Prolyl Endopeptidase Inhibitor 1 (Boc-Pro-prolinal) is a potent **prolyl endopeptidase (PEP; PE)** inhibitor, with a K_i value of 15 nM. Prolyl Endopeptidase Inhibitor 1 has anti-amnesic effect.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Puromycin aminonucleoside

(NSC 3056) Cat. No.: HY-15695

Puromycin aminonucleoside (NSC 3056) is the aminonucleoside portion of the antibiotic puromycin, and used in nephrosis animal models. Puromycin aminonucleoside induces **apoptosis**.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g

Retagliptin

(SP2086) Cat. No.: HY-112668A

Retagliptin (SP2086) is a selective, competitive and orally active **dipeptidyl peptidase-4 (DPP-4)** inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Retagliptin phosphate

(SP2086 phosphate) Cat. No.: HY-112668

Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active **dipeptidyl peptidase-4 (DPP-4)** inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research.



Purity: 99.89%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Saikogenin A

Cat. No.: HY-N6584

Saikogenin A, extracted from a Chinese herbal plant called Tsai-Fu, is a dipeptidyl peptidase-IV (**DPP-IV**) inhibitor.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg

Saxagliptin

(BMS-477118) Cat. No.: HY-10285

Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active **dipeptidyl peptidase-4 (DPP-4)** (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research.



Purity: 99.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Saxagliptin hydrate

(BMS-477118 hydrate) Cat. No.: HY-10285A

Saxagliptin hydrate (BMS-477118 hydrate) is a potent, selective, reversible, competitive and orally active **dipeptidyl peptidase-4 (DPP-4)** (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin hydrate has the peotential for type 2 diabetes mellitus research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Saxagliptin hydrochloride

(BMS-477118 hydrochloride) Cat. No.: HY-16448

Saxagliptin hydrochloride (BMS-477118 hydrochloride) is a potent, selective, reversible, competitive and orally active **dipeptidyl peptidase-4 (DPP-4)** (K_i = 0.6-1.3 nM) inhibitor. Saxagliptin hydrochloride has the peotential for type 2 diabetes mellitus research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Sitagliptin

(MK-0431) Cat. No.: HY-13749

Sitagliptin (MK-0431) is a potent inhibitor of **DPP4** with an IC_{50} of 19 nM in Caco-2 cell extracts.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

Sitagliptin phosphate

(MK-0431 phosphate) Cat. No.: HY-13749A

Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of **DPP4** with an IC_{50} of 19 nM in Caco-2 cell extracts.



Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

Sitagliptin phosphate monohydrate

(MK-0431 phosphate monohydrate) Cat. No.: HY-13749B

Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate) is a potent inhibitor of **DPP4** with an IC_{50} of 19 nM in Caco-2 cell extracts.



Purity: 99.62%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Sitagliptin-d4 phosphate

Cat. No.: HY-13749AS

Sitagliptin-d4 (MK-0431-d4) phosphate is the deuterium labeled Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of **DPP4** with an IC_{50} of 19 nM in Caco-2 cell extracts.



Purity: >98%
Clinical Data:
Size: 1 mg

Talabostat

(Val-boroPro; PT100)

Cat. No.: HY-13233

Talabostat (Val-boroPro; PT100) is an orally active and nonselective **dipeptidyl peptidase IV (DPP-IV)** inhibitor (IC_{50} < 4 nM; K_i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein **(FAP)** (IC_{50} = 560 nM), inhibits DPP8/9 (IC_{50} = 4/11 nM; K_i =...



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Talabostat isomer mesylate

Cat. No.: HY-13233B

Talabostat isomer mesylate is an isomer of talabostat mesylate. Talabostat (PT100, Val-boroPro) is a potent, nonselective and orally available **dipeptidyl peptidase IV** (DPP-IV) inhibitor with a K_i of 0.18 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Talabostat mesylate

(Val-boroPro mesylate; PT100 mesylate)

Cat. No.: HY-13233A

Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective **dipeptidyl peptidase IV (DPP-IV)** inhibitor (IC_{50} < 4 nM; K_i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein **(FAP)** (IC_{50} = 560 nM), inhibits DPP8/9 (IC_{50} = 4/11...



Purity: 99.05%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Teneligliptin

(MP-513)

Cat. No.: HY-14806

Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting **DPP-4** inhibitor. Teneligliptin competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC_{50}s of approximately 1 nM.



Purity: 99.16%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg

Teneligliptin D8

(MP-513 D8)

Cat. No.: HY-14806S

Teneligliptin D8 (MP-513 D8) a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Teneligliptin hydrobromide

(MP-513 hydrobromide)

Cat. No.: HY-14806A

Teneligliptin (MP-513) hydrobromide is a potent chemotype prolylthiazolidine-based **DPP-4** inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC_{50}s of approximately 1 nM.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 250 mg

Teneligliptin hydrobromide hydrate

(MP-513 hydrobromide hydrate)

Cat. No.: HY-14806B

Teneligliptin hydrobromide hydrate is a potent chemotype prolylthiazolidine-based **DPP-4** inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC_{50}s of approximately 1 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Teneligliptin-d4

(MP-513-d4)

Cat. No.: HY-14806S1

Teneligliptin-d4 is deuterium labeled Teneligliptin. Teneligliptin (MP-513) is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trelagliptin

(SYR-472)

Cat. No.: HY-15408

Trelagliptin (SYR-472) is a potent, orally active and highly selective **DPP-4** inhibitor with an IC_{50} of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).



Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Trelagliptin succinate

(SYR-472 succinate) Cat. No.: HY-15408A

Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective **DPP-4** inhibitor with an IC_{50} of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UAMC00039 dihydrochloride

Cat. No.: HY-101769

UAMC00039 dihydrochloride is a potent, reversible and competitive **dipeptidyl peptidase II** inhibitor with an IC_{50} of 0.48 nM.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vildagliptin

(LAF237; NVP-LAF 237) Cat. No.: HY-14291

Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (**DPP-IV**) inhibitor with an IC_{50} of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.



Purity: 98.18%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Vildagliptin dihydrate

(LAF237 dihydrate; NVP-LAF 237 dihydrate) Cat. No.: HY-14291A

Vildagliptin dihydrate (LAF237 dihydrate) is a potent, stable, selective dipeptidyl peptidase IV (**DPP-IV**) inhibitor with an IC_{50} of 3.5 nM in human Caco-2 cells. Vildagliptin dihydrate possesses excellent oral bioavailability and potent antihyperglycemic activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Vildagliptin-d3

(LAF237-d3; NVP-LAF 237-d3) Cat. No.: HY-14291S

Vildagliptin-d3 (LAF237-d3) is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (**DPP-IV**) inhibitor with an IC_{50} of 3.5 nM in human Caco-2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 µg, 5 mg

Vildagliptin-d7

(LAF237-d7; NVP-LAF 237-d7) Cat. No.: HY-14291S1

Vildagliptin-d7 is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg